Latest news with #WorldVaccineCongress
Business Wire
07-05-2025
- Health
- Business Wire
Vaccines Still Matter – Global Healthy Living Foundation Sees Strong Patient Engagement Despite Current Negative Rhetoric
BUSINESS WIRE)--At a medical conference for vaccine professionals, Global Healthy Living Foundation (GHLF) social media posts, podcasts and YouTube videos had surprising uptake among chronically ill patients, despite continuing anti-vaccine rhetoric from many media, individuals and government sources. ...Surprising uptake among chronically ill patients, despite continuing anti-vaccine rhetoric from many media, individuals and government sources. GHLF's coverage of the World Vaccine Congress, held in Washington, D.C. last week, reached more than 23,000 non-attendees and generated more than 800 engagements across platforms including LinkedIn, X, Instagram, Facebook, TikTok, and YouTube. A special video podcast episode of Healthcare Matters recorded at the conference and published on April 25 has so far garnered more than 4,900 views/listens and continues to climb. 'These aren't big numbers for consumer-oriented social media posts or podcasts,' said Robert Popovian, PharmD, MS, GHLF's Chief Science Policy Officer. 'But GHLF's digital output is organic, high-credibility and tailored to niche audiences of professionals, as well as individuals and caregivers with specific chronic diseases. It isn't necessarily relevant unless you have, or care for someone, with a very specific disease, so these are significant numbers in a short time frame,' he said. 'It signals to us that maintaining and protecting health in the face of a chronic illness is important to this audience. They want information about vaccines, and they understand the value of vaccinations in reaching their health goals,' Dr. Popovian added. 'Before the current drop in vaccination rates among the general public in some areas of the U.S., people with ongoing illnesses who were often immunocompromised, could rely on the overall community immunity to add an extra measure of protection against disease. This extra protection, afforded by healthy vaccinated individuals who felt a responsibility to their neighbors, isn't as prevalent today so we lose community immunity and diseases that were eradicated in the U.S. many years ago are returning,' Popovian added. 'What really struck me at the World Vaccine Congress was how aligned people were — from pharma leaders to advocates to policy folks — about the urgency of fighting misinformation and navigating funding shortfalls. Even with different perspectives, there was a real sense of unity and shared purpose, which left me hopeful about the road ahead, especially with new applications for mRNA vaccines,' Ben Blanc, MS, GHLF's Director of Digital Production and Engagement said. The Healthcare Matters podcast, which proved immediately popular among patients, was recorded live at the Congress and hosted by Dr. Popovian and Mr. Blanc. The episode featured vaccine experts, including: Richard Hughes, Partner at Epstein Becker & Green and Lecturer in Law at George Washington University Tommy Acciani, Director, U.S. Vaccine Policy, GSK Abby Bownas, Co-lead, Adult Vaccine Access Coalition Rekha Lakshmanan, Chief Strategic Officer, The Immunization Partnership The podcast explored the current landscape of adult immunization policy, funding threats to vaccine infrastructure, misinformation challenges, and what's next for vaccine innovation. For continued updates and to access GHLF's World Vaccine Congress content, visit: All interviews, as well as our special video episode, can be found here: About GHLF The Global Healthy Living Foundation is a U.S. based, 501(c)(3) nonprofit, international organization whose mission is to improve the quality of life for people with chronic illnesses by advocating for improved access to health care through education, patient-centered clinical research, support, advocacy, and economic and policy research. GHLF is also a staunch advocate for vaccines. The Global Healthy Living Foundation is the parent organization of CreakyJoints®, the international, digital community for millions of people living with arthritis and their supporters worldwide who seek education, support, activism, and patient-centered research in English, Spanish, and French. In addition to arthritis and autoimmune disorders, GHLF supports dermatology, gastroenterology, neurology, cardiology, oncology, infectious disease, rare disease, and pulmonary patients through a host of different programs and activities which draw more than 700,000 patients a month to GHLF websites and create more than 10 million impressions a month on seven social media platforms. In 2024, GHLF had more than 1 million views and listens with its patient-centered audio-visual content, found on YouTube and podcast platforms. GHLF never asks the public for donations, receiving funding instead through governments, non-governmental organizations, foundations, industry, family foundations, and GHLF Co-Founder Louis Tharp. Visit for more information.
Business Wire
25-04-2025
- Health
- Business Wire
Longhorn Vaccines and Diagnostics Presents Compelling Data on LHNVD-303 Vaccine for Sepsis Related to Bacterial Infections at the World Vaccine Congress
BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)-- Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data at the World Vaccine Congress 2025 on LHNVD-303, the company's composite peptide vaccine for sepsis due to bacterial infections and its applications in inflammatory diseases. The World Vaccine Congress took place in Washington, D.C. from April 22-24. Sepsis is a life-threatening complication of bacterial infections that triggers an immune response to circulating pathogens and toxins while driving systematic inflammation. Current treatments for these bacterial infections rely heavily on antibiotics and supportive care, which is ineffective for the growing number of antimicrobial resistant (AMR) strains. To overcome these challenges, LHNVD-303 contains a breakthrough design as a novel, unconjugated, broad-spectrum peptide vaccine combining conserved epitopes from lipopolysaccharide (LPS), peptidoglycan (PGN), and lipoteichoic acid (LTA) —three key bacterial cell wall components. The vaccine is also formulated with a universal T cell epitope and adjuvanted with AddaVax to boost immunogenicity. 'LHNVD-303 is a broad-based composite peptide vaccine designed to kill gram-positive and gram-negative bacteria and bind and clear the toxins they release, with the goal of preventing bacterial infections and reducing acute and chronic inflammation without compromising the immune system,' said Longhorn Vaccine and Diagnostics President Jeff Fischer. 'In animal studies to date, LHNVD-303 has shown powerful activity in its ability to generate broad antibody responses, kill harmful live bacteria, and bind key toxins that cause systematic inflammation, which could have wide ranging applications from inflammaging to sepsis. We plan to continue our study of LHNVD-303 while rapidly progressing an extended half-life monoclonal antibody cocktail comprised of the same targets.' Longhorn's animal model presentation, titled, 'A Broad-Based Composite Peptide Vaccine Targeting Conserved Bacterial Cell Wall and Toxin Epitopes: Towards the Prevention of Sepsis and Inflammation,' demonstrated several outcomes with transformative global implications. Broad and Effective Antibody Response LHNVD-303 generated high-titer IgG1 antibodies in both mice and pigs against LPS, PGN, and LTA, confirming the ability to target conserved epitopes. Antisera demonstrated strong binding to multiple gram-positive and gram-negative bacteria, including Staphylococcus aureus, Mycobacterium smegmatis, E. coli, and Group B Streptococcus. Functional Efficacy – Not Just Binding, But Killing LHNVD-303 demonstrated potent opsonophagocytic killing activity against live bacteria using U-937 macrophage-like cells. Antibodies promoted functional immune clearance, not just recognition, underscoring their therapeutic relevance. Dual Impact on Infection and Inflammation By targeting conserved bacterial cell wall structures and toxins, the vaccine-induced antibodies are positioned to neutralize pathogens and reduce systemic inflammation—offering protection not only against infection, but also against sepsis and chronic inflammation. LHNVD-303's non-reactogenic profile in pigs supports its safety and tolerability in large animal models. Implications for AMR and Healthy Aging By reducing bacterial burden and inflammatory toxin load, the vaccine holds promise to reduce antibiotic use, a key strategy in addressing the global AMR crisis. It also has the potential to mitigate inflammaging—chronic, low-grade inflammation linked to aging and degenerative diseases—through suppression of bacterial-driven immune activation. For more information about Longhorn, visit About Longhorn Vaccines and Diagnostics Longhorn Vaccines and Diagnostics is a closely held One Health company based in Maryland that is developing broad coverage vaccines and diagnostic tools for worldwide public health concerns such as anti-microbial resistance, sepsis and to prevent future pandemics. Since its inception in 2006, Longhorn has focused on developing broad coverage vaccines and diagnostic tools that can impact a pandemic on a global scale and at all socio-economic levels. Since pandemics flow between humans and animals, Longhorn products play a significant role to surveil, diagnose, prevent and treat the next infectious disease. Longhorn's core diagnostic product, PrimeStore® Molecular Transport Medium (MTM), is a patented, FDA cleared, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations, and drug manufacturers improve the diagnosis and treatment of highly infectious diseases such as Influenza, SARS-CoV-2, and Mycobacterium tuberculosis (TB). Unlike standard devices for collecting and transporting virus samples, PrimeStore® MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization.
Yahoo
23-04-2025
- Business
- Yahoo
Why vaccine makers aren't worried about Trump administration cuts
Large and mid-cap vaccine makers are, as of now, unworried about their 2025 pipelines in the face of research funding declines by the Trump administration and a drop in biotech funding. That's what some of the top vaccine-maker executives told Yahoo Finance this week at the World Vaccine Congress in Washington, D.C. These executives believe there will be no impact from the funding cuts and policies coming down from the Trump administration, while others view it as a four-year storm they will just have to weather before being able to carry on as usual afterward. "We're in this for the long game. We believe in vaccines, in the value of vaccines, and what they bring to public health. Infectious diseases aren't going to go away, so the need for vaccines is going to remain long-term," said Sally Mossman, head of research portfolio strategy at Sanofi (SNY). While large-cap pharma companies can fund most of their research and development internally, they have been known to rely on federal funding for the earliest stages of research via partnerships with research agencies like the National Institutes of Health (NIH). They also partner with smaller biotech companies and academic research centers. But that dynamic is drastically changing under the Trump administration. The NIH has already slashed billions in research funding for top universities and cut funding for one mRNA vaccine study and other studies related to vaccine access and hesitancy. (The trickle-up effect on large caps is yet to be determined.) At the same time, funding for biotech — potential partners or acquisition targets for the big players — is also on the decline as investors continue to lose interest in the post-pandemic world. The view from executives at Pfizer (PFE), Moderna (MRNA), GSK (GSK), Sanofi, and Merck (MRK)? They'll be fine in the long run. Each company has between a dozen and two dozen vaccine candidates actively being developed and tested in its pipeline. Despite recent announcements of cuts and key leadership departures at the FDA, the companies have not experienced any disruptions in communicating with the FDA about the progress of these vaccines. GSK global medical lead for vaccines Rafik Bekkat-Berkani said that paying attention to the (short-term) noise was important, but "whether we need to let this noise dictate what we do, the answer is no." Sanofi's Mossman noted that as the company focuses on the US versus global markets, one goal is always to ensure a return on investment for whatever vaccine is being developed. It's no wonder since vaccines make up a good chunk of revenue, even for large-cap pharmaceuticals with diversified portfolios. Among the companies present, UK-based GSK and France-based Sanofi saw vaccines sales account for about 25% of total revenues in 2024. Pfizer counted its top-selling vaccines as 20% of its $64 billion in revenues last year. Merck saw top-selling vaccine sales contribute less than 20% to its $64 billion in revenues. Moderna is the most heavily reliant on federal funding for some of its pipeline candidates and has only two vaccines on the market: its COVID-19 vaccine and a respiratory syncytial virus (RSV) vaccine for older adults. The two contributed 100% to the company's $3.2 billion in sales last year. Meanwhile, Health and Human Services Secretary Robert F. Kennedy Jr. has expressed an interest in eliminating some childhood vaccines due to concerns about their potential impacts on children. That doesn't worry the companies as much, because adult vaccines are a newer and profitable market to target, the executives said. "I think we have to recognize ... the low-hanging fruit's already (done) to a large degree," Merck associate vice president of vaccines Jeffrey Roberts said. It's why more novel viruses and diseases are being targeted — and those that have been targeted globally for some time, like Lyme disease. Other areas are in early stages, like a vaccine for acne at Sanofi. Mossman explained that while some might consider acne an unimportant target, she sees it as a solution to an inflammatory skin problem for about 22 million patients. Merck's Roberts said the remaining vaccines to target are "tough nuts to crack." Which is why the group collectively waved off any threats from the Trump administration's moves. "It comes down to 'Don't worry about the money. If you make something that has value, people are going to value it,'" Roberts said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices
Yahoo
16-04-2025
- Business
- Yahoo
Dyadic to Present at World Vaccine Congress
JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ('Dyadic', 'we', 'us', 'our', or the 'Company') (Nasdaq: DYAI), a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines for the efficient large-scale manufacture of proteins for use in human and animal reagents, vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications today announced that Mark Emalfarb, Chief Executive Officer, will present at the 2025 World Vaccine Congress in Washington, D.C. World Vaccine Congress | Washington, 22–24, 2025Presentation: Wednesday, April 23, 2025 | 12:40 PM–1:10 PMTrack: Influenza & Respiratory | Room 202ATopic: C1 Platform: The Urgent Need for Smarter Biomanufacturing – A Call to Action on Avian Influenza (H5N1) & Future Pandemics During the presentation, Mr. Emalfarb will provide an overview of recent preclinical research utilizing Dyadic's proprietary C1 expression platform, including data related to the production of non-mRNA antigens and reagents for vaccine production. 'We are excited to share the latest pre-clinical data from multiple studies demonstrating that Dyadic's proprietary C1 platform enables the production of non-mRNA antigens that elicit high neutralizing antibodies,' said Mr. Emalfarb. 'Leveraging our C1 platform, we aim to enable rapid, cost-effective production of antigens, reagents and cell culture media products to address significant global health challenges, including avian influenza and future pandemics, through scalable and efficient biomanufacturing to meet the growing demand for rapid-response vaccines and therapeutics, paving the way for a more resilient global health infrastructure.' Dyadic's management team will be available for meetings throughout the conference. To schedule a meeting, please contact assistant@ or visit booth #654 during the event. About Dyadic International, Inc. Dyadic International, Inc., is a biotechnology company that utilizes its microbial production platforms to develop commercial cell lines focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. Dyadic's microbial gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead platform, the C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and potentially improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness. Dyadic is focusing on leveraging its microbial platform technologies for itself and its collaborators in a wide range of applications, including human and animal vaccines, therapeutics, food, nutrition, wellness, and internal biological products. For more information about Dyadic International, visit Safe Harbor Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled 'Risk Factors' in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at Contact:Dyadic International, W. RawsonChief Financial OfficerPhone: (561) 743-8333Email: ir@
Yahoo
16-04-2025
- Business
- Yahoo
Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025
CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025, which will be held in Washington, D.C., April 22-24, 2025. A copy of the Company's presentation will be available under the Scientific Presentations tab of the Tonix website at following the conference. Additional meeting information can be found on the World Vaccine Congress website here. Presentation Details Presenter: Farooq Nasar, PhD, Senior Principal Investigator, Research and Development Center, Tonix Pharmaceuticals Session: Emerging & Re-emerging Diseases Title: A Novel Single-Dose, Attenuated Live, Minimally Replicative Mpox Vaccine Location: Room 202B Date: Wednesday, April 23, 2025 Time: 10:10 a.m. Panel Details Moderator: Zeil Rosenberg, M.D., M.P.H., Executive Vice President, Medical, Tonix Pharmaceuticals Session: Emerging & Re-emerging Diseases Title: Mpox and Smallpox Threats: Vaccine Development and Biosecurity Policy Location: Room 202B Date: Wednesday, April 23, 2025 Time: 3:25 p.m. Tonix Pharmaceuticals Holding Corp.* Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix's development portfolio is focused on central nervous system (CNS) disorders. Tonix's priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix's CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the National Institute on Drug Abuse. Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix's infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD's Defense Threat Reduction Agency (DTRA) for up to $34 million over five years. TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. * Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as 'anticipate,' 'believe,' 'forecast,' 'estimate,' 'expect,' and 'intend,' among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the 'SEC') on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor Contact Jessica MorrisTonix (862) 799-8599 Peter VozzoICR (443) 213-0505 Media Contact Ray Jordan Putnam Insights ray@ (949) 245-5432 Indication and Usage Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine. Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age. Important Safety Information Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack: discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem. Do not use Zembrace or Tosymra if you have: history of heart problems narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease) uncontrolled high blood pressure hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider. had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation severe liver problems taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure. are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure. an allergy to sumatriptan or any of the components of Zembrace or Tosymra Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements. Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert. Zembrace and Tosymra may cause serious side effects including: changes in color or sensation in your fingers and toes sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet increased blood pressure including a sudden severe increase even if you have no history of high blood pressure medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider. serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking. hives (itchy bumps); swelling of your tongue, mouth, or throat seizures even in people who have never had seizures before The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only). Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider. This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit or call 1-888-869-7633. You are encouraged to report adverse effects of prescription drugs to the FDA. Visit or call in to access your portfolio
